Short CV/Education and training


  • 1977
    High school degree, latin-greek-philosophy, Como, Italy

  • 1981
    Bachelor of Science in Pharmacology & Toxicology, Biochemistry and Vegetal Physiology, University of Lausanne.

  • 1986
    Doctor of Philosophy in Toxicology, mention "summa cum laude" University of Lausanne, Switzerland.

  • 1998

Professional experience:

  • 1987
    Postdoctoral fellow Institute of Pharmacology & Toxicology, University of Lausanne (Prof. J. Diezi)

  • 1988
    Postdoctoral fellow, Occupational Health Sciences Institute, University of Lausanne, Switzerland (Prof. H.Savolainen & Prof.M. Guillemin)

  • 1988 – 1991
    Postdoctoral fellow at the Swiss Institute on Experimental Cancer Research, Epalinges, Switzerland (Dr. P. Cerutti)

  • 1991 – 1993
    Postdoctoral fellow at the National Cancer Institute, Laboratory of Human Carcinogenesis, National Cancer Institute, Bethesda, USA (Dr. C.C. Harris)

  • 1993 – 1999
    Lecturer, Institute of Pharmacology & Toxicology, University of Lausanne (Prof. J. Diezi)

  • 1999 – 2006
    Substitute Assistant professor, Institute of Pharmacology & Toxicology, University of Lausanne

  • 2006
    Invited scientist DKFZ, Heidelberg

  • since 2007
    group leader, Laboratory of Molecular Oncology, Dept Thoracic Surgery, Lungen- und Thoraxonkologie Zentrum of Zurich University Hospital

Selected publications

  • Okonska A and Felley-Bosco E, “BAP1 missense mutations in cancer: friend or foe?” Trends in Cancer 2019. doi: 10.1016/j.trecan.2019.09.006, in press

  • Okonska A, Bühler S, Rao V, Ronner M, Blijlevens M, van der Meulen-Muileman IH, de Menezes RX, Wipplinger M, Oehl K, Smit EF, Weder W, Stahel RA, Penengo L, van Beusechem VW, Felley-Bosco E. “Functional genomic screen in mesothelioma reveals that loss of function of BRCA1-associated-protein-1 induces chemoresistance to ribonucleotide reductase inhibition” Mol Cancer Ther. 2019 Oct 16. pii: molcanther.0356.2019. doi: 10.1158/1535-7163.MCT-19-0356. [Epub ahead of print] PMID: 31619462

  • Kresoja-Rakic J, Szpechcinski A, Kirschner MB, Ronner M, Minatel B, Martinez VD, Lam WL, Weder W, Stahel R, Früh M, Cerciello F, Felley-Bosco E. “miR-625-3p and lncRNA GAS5 in Liquid Biopsies for Predicting the Outcome of Malignant Pleural Mesothelioma Patients Treated with Neo-Adjuvant Chemotherapy and Surgery” Noncoding RNA. 2019 Jun 17;5(2). pii: E41. doi: 10.3390/ncrna5020041. PMID: 31212997

  • Kresoja-Rakic J, Felley-Bosco E. Desthiobiotin-Streptavidin-Affinity Mediated Purification of RNA-Interacting Proteins in Mesothelioma Cells. J Vis Exp. 2018 Apr 25;(134). doi: 10.3791/57516. PMID: 29757292

  • Felley-Bosco E, Rehrauer H. Non-Coding Transcript Heterogeneity in Mesothelioma: Insights from Asbestos-Exposed Mice. Int J Mol Sci. 2018 Apr 11;19(4). pii: E1163. doi: 10.3390/ijms19041163. PMID: 29641489

  • Oehl K, Kresoja-Rakic J, Opitz I, Vrugt B, Weder W, Stahel R, Wild P, Felley-Bosco E. Live-Cell Mesothelioma Biobank to Explore Mechanisms of Tumor Progression. Front Oncol. 2018 Feb 23;8:40. . PMID: 29527515

  • Hubert Rehrauer, Licun Wu, Walter Blum, Lazslo Pecze, Thomas Henzi, Véronique Serre-Beinier, Catherine Aquino, Bart Vrugt, Marc de Perrot, Beat Schwaller, Emanuela Felley-Bosco. How asbestos drives the tissue towards tumors: YAP activation, macrophage and mesothelial precursor recruitment, RNA editing and somatic mutations. Oncogene, 37(20):2645-2659.

  • Kresoja-Rakic, J.; Sulemani, M.; Kirschner, M.B.; Ronner, M.; Reid, G.; Kao, S.; Schwaller, B.; Weder, W.; Stahel, R.A.; Felley-Bosco, E. Posttranscriptional regulation controls calretinin expression in malignant pleural mesothelioma. Frontiers in Genetics 29 May 2017 |

  • Parrotta R, Okonska A, Ronner M, Weder W, Stahel R, Penengo L, Felley-Bosco E. A Novel BRCA1-Associated Protein-1 Isoform Affects Response of Mesothelioma Cellsto Drugs Impairing BRCA1-Mediated DNA Repair. J Thorac Oncol. 2017 Apr 4. pii:S1556-0864(17)30274-5. doi: 10.1016/j.jtho.2017.03.023. PubMed PMID: 28389374.

Complete list of publications

Selected projects

  • RNA editing in mesothelioma

  • From asbestos-exposure to cancer: a systemic approach to detect loss of homeostatic control in the mesothelial environment

  • Preclinical Malignant Pleural Mesothelioma Models To Accelerate Clinical Research On Targeted Therapies

Membership in scientific bodies/juries

  • Swiss Society of Pharmacology and Toxicology , IASLC

Media coverage



You can only see the contact information of the academics in the database if you are a registered user of AcademiaNet.
Please register here


  1. Read what our members say about AcademiaNet.

Follow us

Similar profiles

  1. PhD My Andersson

    Biological and related sciences, Health, Neurophysiology (synaptic physiology)

  2. Prof. Dr. Katrin Amunts

    Health, Brain research

  3. Prof. Anne Angelillo-Scherrer

    Biological and related sciences, Health, Hematology, Internal Medicine; Special focus: hemostasis and thrombosis, laboratory diagnosis particularly in the field of hemostasis and thrombosis, myeloproliferative neoplasms and their bleeding/thrombotic complications

  4. Dr. Ana Allende

    Agriculture, Health, Food Safety

Academia Net